#We are not waiting - DIY APS Do-It-Yourself Artificial Pancreas Systems: The story so far

IF 0.4 Q4 ENDOCRINOLOGY & METABOLISM British Journal of Diabetes Pub Date : 2022-12-22 DOI:10.15277/bjd.2022.373
T. Crabtree, B. Ryder, E. Wilmot
{"title":"#We are not waiting - DIY APS Do-It-Yourself Artificial Pancreas Systems: The story so far","authors":"T. Crabtree, B. Ryder, E. Wilmot","doi":"10.15277/bjd.2022.373","DOIUrl":null,"url":null,"abstract":"Introduction In 2015 Dana Lewis, a person with diabetes, developed her own hybrid-closed loop system and began the #WeAreNotWaiting movement (Figure 1). These systems, often called “do-it-yourself” artificial pancreas systems (DIY APS) or open-source closed-loop automated insulin delivery systems, combine an insulin pump, a sensor and an algorithm to maintain glucose levels in range. Whilst early versions were “hybrid” – in other words they still required manual bolusing-the newer versions of the algorithm have been used as a fully-closed loop (no bolus required!) by some individuals. An article written in 2019 provides further detail on these systems and some of the issues associated with them.1 These systems filled a gap by circumnavigating the approvals that commercial companies require in order to launch similar systems. There are three systems commonly encountered: OpenAPS, AndroidAPS and Loop.1 At the time of writing all three systems are unapproved and unregulated. When these systems first entered UK services the evidence was limited. However, self-reported outcomes from users of the systems were encouraging from both glycaemia and safety points of view.2-4 At that time, the approach taken across UK diabetes services was inconsistent and guidelines from the General Medical Council and others were unclear.5 Work was undertaken to explore the opinions of UK healthcare professionals; initial position statements were produced by Diabetes UK and other organisations to support users of these systems.6,7 We also explored the concerns of individuals with diabetes commencing the use of these systems, and were able to demonstrate that they were less concerned with safety and","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15277/bjd.2022.373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction In 2015 Dana Lewis, a person with diabetes, developed her own hybrid-closed loop system and began the #WeAreNotWaiting movement (Figure 1). These systems, often called “do-it-yourself” artificial pancreas systems (DIY APS) or open-source closed-loop automated insulin delivery systems, combine an insulin pump, a sensor and an algorithm to maintain glucose levels in range. Whilst early versions were “hybrid” – in other words they still required manual bolusing-the newer versions of the algorithm have been used as a fully-closed loop (no bolus required!) by some individuals. An article written in 2019 provides further detail on these systems and some of the issues associated with them.1 These systems filled a gap by circumnavigating the approvals that commercial companies require in order to launch similar systems. There are three systems commonly encountered: OpenAPS, AndroidAPS and Loop.1 At the time of writing all three systems are unapproved and unregulated. When these systems first entered UK services the evidence was limited. However, self-reported outcomes from users of the systems were encouraging from both glycaemia and safety points of view.2-4 At that time, the approach taken across UK diabetes services was inconsistent and guidelines from the General Medical Council and others were unclear.5 Work was undertaken to explore the opinions of UK healthcare professionals; initial position statements were produced by Diabetes UK and other organisations to support users of these systems.6,7 We also explored the concerns of individuals with diabetes commencing the use of these systems, and were able to demonstrate that they were less concerned with safety and
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
#我们没有等待-DIY APS自助式人工胰腺系统:迄今为止的故事
2015年,糖尿病患者Dana Lewis开发了自己的混合闭环系统,并开始了#我们不等待运动(图1)。这些系统通常被称为“自己动手”人工胰腺系统(DIY APS)或开源闭环自动胰岛素输送系统,结合胰岛素泵、传感器和算法来维持血糖水平在一定范围内。虽然早期的版本是“混合”的——换句话说,它们仍然需要手动加药——但一些人已经将新版本的算法用作全闭环(不需要加药!)。2019年写的一篇文章提供了有关这些系统以及与之相关的一些问题的进一步细节这些系统绕过了商业公司推出类似系统所需的审批,填补了这一空白。通常会遇到三种系统:OpenAPS、AndroidAPS和Loop.1。在撰写本文时,这三种系统都是未经批准和不受监管的。当这些系统首次进入英国服务时,证据有限。然而,从血糖和安全性的角度来看,系统用户自我报告的结果令人鼓舞。2-4当时,整个英国糖尿病服务机构采取的方法不一致,来自总医学委员会和其他机构的指导方针也不明确开展了探索英国保健专业人员意见的工作;最初的立场声明是由英国糖尿病和其他组织制作的,以支持这些系统的用户。6,7我们还探讨了开始使用这些系统的糖尿病患者的担忧,并能够证明他们对安全性和安全性的担忧较少
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
British Journal of Diabetes
British Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
自引率
16.70%
发文量
15
期刊最新文献
ABCD News Congenital hyperinsulinism: a family case report factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme Fibrates: past history or renaissance? PCSK9 inhibitor therapy: delayed-onset cutaneous reactions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1